Osteoclasts are bone cells that resorb bone tissue by dissolving its mineralized matrix and breaking up the organic bone. Kolliker discovered osteoclasts 1873 [6] ; however, their activity has only recently been elucidated. Osteoclasts are formed from monocytes [7] . Their formation requires the presence of the nuclear factor κB (NF-κB) receptor activator (RANK), the receptor's ligand (RANKL), and macrophage colony-stimulating factor (M-CSF). Neighboring stromal cells and osteoblasts produce these membrane proteins, thus requiring direct contact between these cells and osteoclast precursors. M-CSF acts through its receptor the osteoclast colony-stimulating factor 1 receptor (c-fms), a transmembrane tyrosine kinase receptor, leading to secondary messenger activation of the tyrosine kinase Src. Both molecules are necessary for osteoclastogenesis and are widely involved in the differentiation of monocyte/macrophage-derived cells. RANKL is a member of the tumor necrosis factor family of proteins and is essential in osteoclastogenesis. RANKL activates NF-κB and nuclear factor of activated T cells (NFATc1) by activating RANK. Osteoclast differentiation is inhibited by osteoprotegerin, which is produced by osteoblasts and binds to RANKL thereby preventing interaction with RANK.
Smink et al. [8] now show that C/EBPβ is a determinant of giant osteoclast formation in GCT and that a pharmacological treatment for GCT could possibly be applied to inhibit tumor growth. How can we tie these components together? The answers follow years of effort from the Leutz laboratory [9] [10] [11] [12] [13] . The story begins with their elucidation of how translational control of C/EBPβ isoforms is regulated. From a common C/EBPβ mRNA, small upstream openreading frames (uORF) mediate translational control and thereby regulate the expression of long and truncated protein isoforms, as shown for C/EBPβ in Fig. 1 . C/EBPβ mRNA translates into two long protein isoforms known as liver-activating protein (LAP and LAP*) and the truncated liver inhibitory protein (LIP). The pathway that determines whether C/EBPβ mRNA makes LAP or LIP is mammalian target of rapamycin (mTOR). mTOR is a serine/threonine protein kinase that belongs to the phosphatidylinositol 3-kinase-related kinase protein family. The pathway functions as a nutrient energy/redox sensor and regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, transcription, and as we see here, also translation. The Leutz laboratory has recently reviewed the mechanisms how uORF regulate C/EBPβ mRNA isoform production [10] . Under the influence of mTOR activation, C/EBPβ mRNA produces more LIP and less LAP. The LIP isoform is commonly expressed in cancers, such as Hodgkin's disease, anaplastic large-cell lymphoma, breast cancer, and as shown by Smink et al. here, in GCT [8] . The drug rapamycin (generic name sirolimus) inhibits mTOR and therefore can steer C/EBPβ mRNA into making LAP, rather than LIP.
Smink et al. showed earlier how C/EBPβ differentially affects bone mass [11] . The group found that rapamycin inhibited osteoclast generation from monocyte precursors in wild-type mice. They then used C/EBPβ gene-deleted mice to show that osteoclast precursors in these mice were not influenced by rapamycin. The C/EBPβ gene-deleted mice also exhibited increased bone reabsorption because of dysregulated osteoclast activity. Furthermore, the V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (MafB) transcription factor was downregulated in these mice. The group then found that expression of the LAP and LIP isoforms in monocytes differentially affected MafB promoter activity. Their data revealed that the C/EBPβ LIP isoform downregulates MafB gene expression, while the LAP isoform enhanced MafB expression. Moreover, ectopic expression in monocytes of either LAP or LIP C/EBPβ isoforms dramatically affected osteoclastogenesis and "knock in" mice that expressed only the LAP or the LIP isoforms instead of the wild-type C/EBPβ gene had tiny or massively enlarged osteoclasts in their bones, respectively [11, 12] . We can imagine a schema in which monocyte precursors are transformed to osteoclasts largely through the C/EBPβ LIP isoform via attenuation of MafB. mTOR pathway activity modulates this process, as shown in Fig. 2 .
In the current report, Smink et al. [8] suggest that clinical utility can be derived from their findings, particularly for patients with GCT. Inhibition of mTOR signaling has become standard practice in transplantation medicine and is also used in the treatment of various malignancies, notably renal cell carcinoma. Another more common bone disease that comes to mind is Paget's disease of bone (PDB). Histologically, the primary affected cells in PDB are osteoclasts that are numerous, enlarged, hypermultinucleated, and hyperactive probably because of RANKL hypersensitivity [14] . A downside could be the inhibition of normal bone growth and turnover by mTOR inhibition. Alvarez-Garcia et al. [15] investigated the effects of rapamycin on longitudinal bone growth. They gave 4-week-old rats rapamycin daily for 2 weeks. Rapamycin-treated rats were growth retarded and had marked alterations in their growth plates, compared to controls. Interestingly, osteoclasts were reduced, particularly near to the chondroosseus junctions. However, also conceivable would be the concomitant administration of an mTOR inhibitor along with denosumab, a human monoclonal antibody with high affinity to RANKL, which would inhibit RANK signaling. In that way, toxicity from mTOR inhibition could be held to a minimum. Translating basic findings to clinical medicine is never easy, but understanding mechanisms is always the first step.
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